|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
University of Nebraska National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00617799 |
Purpose
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at biomarkers that predict response to high-dose aldesleukin in patients with metastatic kidney cancer or metastatic melanoma.
| Condition | Intervention |
|---|---|
|
Kidney Cancer Melanoma (Skin) |
Biological: aldesleukin Genetic: gene expression analysis Genetic: mutation analysis Other: flow cytometry |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Pilot Study to Identify Biomarkers That May Predict Response to High Dose IL-2 |
| Estimated Enrollment: | 15 |
| Study Start Date: | October 2007 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: Patients receive high-dose aldesleukin (IL-2) as part of standard treatment on days 1 and 8. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection at baseline, prior to beginning course 2, and 4 weeks after the completion of course 2. Samples are analyzed using peripheral blood cytometry, gene microarray analysis, and IL-2 receptor single-nucleotide polymorphism techniques.
Eligibility| Ages Eligible for Study: | 19 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Contacts and Locations| United States, Nebraska | |
| UNMC Eppley Cancer Center at the University of Nebraska Medical Center | |
| Omaha, Nebraska, United States, 68198-6805 | |
| Principal Investigator: | Ralph Hauke, MD | University of Nebraska |
More Information
| Study ID Numbers: | CDR0000582909, UNMC-27807 |
| Study First Received: | February 15, 2008 |
| Last Updated: | June 16, 2009 |
| ClinicalTrials.gov Identifier: | NCT00617799 History of Changes |
| Health Authority: | United States: Federal Government |
|
stage IV renal cell cancer stage IV melanoma |
|
Anti-Infective Agents Urinary Tract Neoplasm Kidney Cancer Anti-HIV Agents Urogenital Neoplasms Urologic Neoplasms Antiviral Agents Melanoma Carcinoma Neuroendocrine Tumors Neuroectodermal Tumors Aldesleukin |
Renal Cancer Anti-Retroviral Agents Urologic Diseases Kidney Neoplasms Nevus, Pigmented Neoplasms, Germ Cell and Embryonal Carcinoma, Renal Cell Neuroepithelioma Nevus Kidney Diseases Adenocarcinoma Neoplasms, Glandular and Epithelial |
|
Anti-Infective Agents Antineoplastic Agents Neoplasms, Nerve Tissue Urogenital Neoplasms Urologic Neoplasms Melanoma Neoplasms by Site Urologic Diseases Anti-Retroviral Agents Kidney Neoplasms Neoplasms, Germ Cell and Embryonal Therapeutic Uses Nevi and Melanomas |
Kidney Diseases Neoplasms by Histologic Type Anti-HIV Agents Antiviral Agents Pharmacologic Actions Carcinoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Aldesleukin Carcinoma, Renal Cell Adenocarcinoma Neoplasms, Glandular and Epithelial |
